EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
Trial details
- Registry ID
- NCT06390059
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Abraxane
| No regulatory events match this view.This does not mean no FDA events have occurred. |